**Core Concept**
The renin-angiotensin-aldosterone system (RAAS) plays a crucial role in regulating blood pressure and electrolyte balance. Renin is a key enzyme in this cascade, initiating a series of reactions that ultimately lead to vasoconstriction and increased blood pressure. Inhibiting renin can be an effective strategy to lower blood pressure in patients with hypertension.

**Why the Correct Answer is Right**
Aliskiren is a direct renin inhibitor, meaning it blocks the action of renin at the level of the angiotensinogen to angiotensin I conversion. This is distinct from angiotensin-converting enzyme (ACE) inhibitors, which block the conversion of angiotensin I to angiotensin II. By inhibiting renin, aliskiren reduces the production of angiotensin II, leading to vasodilation and decreased blood pressure.

**Why Each Wrong Option is Incorrect**
**Option A:** Losartan is an angiotensin II receptor antagonist, not a renin inhibitor. It blocks the action of angiotensin II on its receptor, but does not affect the production of angiotensin II.

**Option B:** Candesartan is another angiotensin II receptor antagonist, similar to losartan. It is not a renin inhibitor and does not affect the RAAS cascade at the level of renin.

**Option C:** Enalapril is an ACE inhibitor, which blocks the conversion of angiotensin I to angiotensin II. While it is effective in lowering blood pressure, it is not a renin inhibitor.

**Clinical Pearl / High-Yield Fact**
Renin inhibitors like aliskiren are a valuable addition to the treatment armamentarium for hypertension, particularly in patients with resistant hypertension or those who cannot tolerate ACE inhibitors or angiotensin receptor blockers.

**Correct Answer: C. Enalapril is an ACE inhibitor, which blocks the conversion of angiotensin I to angiotensin II. While it is effective in lowering blood pressure, it is not a renin inhibitor.**